A Study in Leukemia Patients With Karonudib

Summary

The primary objective of this study is to determine safety and tolerability of Karonudib for the treatment of hematological malignancies. Secondary objectives are to determine a recommended RP2D and schedule for further development of Karonudib, to determine the pharmacokinetics of Karonudib, to look for evidence of treatment efficacy. Overall survival will also be recorded.

Timeline

Start

2019-12-03

Primary completion

2026-12-30

Completion

2026-12-30

Drugs

Indications